Insider buying signals a bullish outlook for ImageneBio, with key insiders purchasing options at a 52‑week low, hinting at potential upside and upcoming milestones.
Insider buying surge at ImageneBio shows confidence in its biotech pipeline, yet warrants carry a 19.99% blocker and potential dilution risk—watch for key clinical milestones and market impacts.